Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
103.52
+0.08 (0.08%)
At close: Jul 24, 2025, 4:00 PM
104.50
+0.98 (0.95%)
After-hours: Jul 24, 2025, 7:51 PM EDT

Company Description

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.

In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension.

Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue.

The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated
Insmed logo
CountryUnited States
Founded1988
IPO DateJun 1, 2000
IndustryBiotechnology
SectorHealthcare
Employees1,271
CEOWilliam Lewis

Contact Details

Address:
700 US Highway 202/206
Bridgewater, New Jersey 08807
United States
Phone908 977 9900
Websiteinsmed.com

Stock Details

Ticker SymbolINSM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001104506
CUSIP Number457669307
ISIN NumberUS4576693075
Employer ID54-1972729
SIC Code2834

Key Executives

NamePosition
William H. Lewis J.D., M.B.A.President, Chief Executive Officer and Chairman
Sara M. Bonstein M.B.A.Chief Financial Officer
Roger Adsett M.B.A.Chief Operating Officer
John Drayton Wise M.B.A.Consultant
Dr. Martina Flammer M.B.A., M.D.Chief Medical Officer
Brian K. Kaspar Ph.D.Chief Scientific Officer
Bryan DunnVice President of Investor Relations
Michael Alexander Smith J.D.Chief Legal Officer and Corporate Secretary
Claire MulhearnVice President of Corporate Communications
S. Nicole Schaeffer M.B.A.Chief People Strategy Officer

Latest SEC Filings

DateTypeTitle
Jul 21, 2025144Filing
Jul 17, 2025SCHEDULE 13G/AFiling
Jul 15, 2025144Filing
Jul 15, 2025144Filing
Jul 11, 2025144Filing
Jul 7, 2025144Filing
Jul 1, 2025144Filing
Jun 23, 2025144Filing
Jun 23, 2025144Filing
Jun 16, 2025144Filing